CEBPA PCR

Diagnostic Use

Test to determine if one or more variants are present in the CEBPA (CCAAT/enhancer binding protein alpha) gene of AML patients.
This provides prognostic information at diagnosis.

NOTE: CEBPA variants may also be detected on the Myeloid NGS Panel at a sensitivity of 5%. However, this panel may not call large insertion/deletion variants and coverage may not be optimal over the CEBPA gene. Please refer to the Myeloid NGS Panel in Test Manager for more details and price.

Department

Genetics - Molecular Pathology

Delphic Registration Code

MOST

Laboratory Handling

Phlebotomy

2x EDTA (Lavender) dedicated to Genetics (same sample can be used for FLT3/NPM1/CEBPA testing)

Registration

Send to MONC

Turnaround Time

14 days

Test Code

5035

Specimen Type

• Whole Blood
• Bone Marrow

Specimen Requirements

Tube/Container Type:

Preferred

• EDTA (Lavender Cap)

Acceptable

• RPMI (Bone Marrow)

Additional Specimen Information

8 ml peripheral blood in EDTA. 1-3 ml of bone marrow in EDTA or RPMI (anticoagulant).
Send ambient to the laboratory.

Aliquot Instructions

Test Method

The CEBPA gene Is amplified by PCR and screened for insertion/deletion variants by fragment analysis. Sanger sequencing is only used to characterise variants detected by fragment analysis and screen for a second nucleotide substitution variant. CEBPA nucleotide substitution variants rarely occur on their own and will not be detected by the fragment analysis method.

Non-Funded Test Cost

$443.08 (Exclusive of GST)

Billing Code

05041

Contact Information

Enquiry Form